Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 13 of 13 publications.

Gini R, Messina D, Aarts W, Paoletti O, Bartolini CC, Weibel D, Choi J, Cid-Royo A, Elbers RJK, Vaz TA, Belitser SV, Bots SH, Riefolo F, Plana E, Sturkenboom MC. Representation of study scripts to improve transparency and efficiency in multidatabase distributed vaccine studies. Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):600-1. doi: 10.1002/pds.5687

Weibel D, De Luise C, Elbers R, van den Bor R, Martin I, Cid-Royo A, Plana E, Garcia de Albeniz Martinez X, Weinrib R, Yefimenko N, Poblador-Plou B, Marconi E, Barbieri E, Stona L, Swart KMA, Roy D, Hyeraci G, Bartolini C, Lupattelli A, Villalobos F, Kendrick K, Garg R, Rubino H, Eijkemans R, Sturkenboom M, Arana A. Utilisation patterns of the COVID-19 mRNA vaccine (Comirnaty®) from the VAC4EU active safety surveillance study in five European countries. Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):173-4. doi: 10.1002/pds.5687

Weibel D, Sturkenboom M, Eijkemans R, van den Bor R, Elbers R, Plana E, Garcia de Albeniz X, Weinrib R, Yefimenko N, Bianchini E, Stona L, Poblador-Plou B, Swart-Polinder K, Bartolini C, Hyeraci RG, Roy D, Lupattelli A, Villalobos F, Barbieri E, Garg RK, Rubino H, De Luise C, Arana A. VAC4EU active safety surveillance study of the BNT162b2 COVID-19 vaccine in five European countries: study design and first results. Poster presented at the 2022 ICPE Conference; August 30, 2022. Copenhagen, Denmark. [abstract] Pharmacoepidemiol Drug Saf. 2022 Sep 23; 31(S2):627-8. doi: 10.1002/pds.5518

Plana E, Rivero-Ferrer E, Aguado J, Saigi-Morgui N, Nuevo J, Daoud SZ, Lei A, Perez-Gutthann S, Rebordosa C. Hospitalization for heart failure among patients using aclidinium bromide and other COPD medications: a post-authorisation safety study in the CPRD. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):1153. doi: 10.1002/pds.4864

Aguado J, Plana E, Saigi N, Garcia-Gil E, Castellsague J, Perez-Gutthann S, Rebordosa C. The missing puff: results of multiple imputation of ppFEV1 in CPRD. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):211-2. doi: 10.1002/pds.4629

Plana E, Rebordosa C, Aguado J, Saigi N, Garcia-Gill E, Castellsague J, Perez-Gutthann S. To pile or not to pile: how to define episodes of use of COPD medications in the CPRD. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 24, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):123. doi: 10.1002/pds.4629

Plana E, Rebordosa C, Aguado J, Thomas S, Garcia-Gil E, Perez-Gutthann S, Castellsague J. Assessment of COPD severity in the UK CPRD. Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 30, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):576. doi: 10.1002/pds

Odom D, Zhou X, Thomas S. Reporting of the trimmed population in propensity score analyses. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):147-8.

Plana E, McGrath LJ, Fortuny J, Ruigomez A, Fernandez-Cantero O, Garcia-Rodriguez LA, Gilsenan AW, Andrews E, Rebordosa C, Ziemiecki R. An algorithm to identify duplicate patients when pooling aggregate data from two primary care databases in the United Kingdom. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):58-9. doi: 10.1002/pds

Afonso ASM, Schmiedl S, Becker C, Primatesta P, Plana E, Souverin PC, Korevaar JC, Hasford J, Reynolds R, de Groot MCH, Schlienger RG, Klungel OH, Rottenkolber M. Association between inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction: a methodological comparison of two databases. Poster presented at the 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; October 2014. Taipei, China. [abstract] Pharmacoepidemiol Drug Saf. 2014 Oct; 23(S1):390-1.

Varas-Lorenzo C, Castellsaque J, Stang MR, Perez-Gutthann S, Aguado J, Rodriguez LA. The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1016-25.

Varas-Lorenzo C, Castellsaque J, Stang MR, Tomas L, Aguado J, Perez-Gutthann S. Positive predictive value of icd-9 codes 410-411 for acute coronary syndromes: saskatchewan hospital automated database. Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):842-52.

Gimeno V, Bernat M, Stang MR, Aguado J, Castellsague J, Perez-Gutthann S. Validity of ICD9-codes for upper gastrointestinal bleeding in the Saskatchewan health databases. Poster presented at the 22nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 24, 2006. Lisbon, Portugal. [abstract] Pharmacoepidemiol Drug Saf. 2006 Aug; 15(S1):S231-2.